A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
At a glance
- Drugs JNJ-64991524 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 08 Aug 2018 Planned primary completion date changed from 13 Jul 2018 to 20 Dec 2018.
- 11 Jul 2018 Planned End Date changed from 21 Nov 2018 to 20 Dec 2018.
- 05 Apr 2018 Planned number of patients changed from 96 to 84.